| Bioactivity | EGFR-IN-107 (compound 3r) is an orally active EGFR inhibitor with IC50 values of 0.4333 μM for EGFRWT and 0.0438 μM for EGFRL858R/T790M. EGFR-IN-107 has anti-proliferative activity and can inhibit the proliferation of H1975 cells and induce their apoptosis. EGFR-IN-107 can be used in cancer research[1]. |
| Invitro | EGFR-IN-107 对 EGFRL858R/T790M 激酶的 IC50 值为 5 nM[1]。EGFR-IN-107 对 Osimertinib (HY-15772) 耐药 H1975 细胞系 (H1975OR) 的 IC50 值为 1.9 μM[1]。EGFR-IN-107 (1 μM, 24 小时) 在 H1975 细胞中能诱导细胞凋亡及抑制细胞迁移[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> EGFR-IN-107 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | EGFR-IN-107 (compound 3r) (5, 10, 20 mg/kg; 口服; 21 天) 在 H1975 异种移植小鼠模型中具有较强的抗肿瘤活性，并且能够显著抑制 H1975 异种移植小鼠模型的增殖[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C34H36FN7O2 |
| Molar Mass | 593.69 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Feng R, et al. Late-stage modification of complex drug: Base-controlled Pd-catalyzed regioselective synthesis and bioactivity of arylated osimertinibs. Sci Adv. 2024 Mar 8;10(10):eadl0026. |